IGC Pharma, Inc.
IGC Pharma, Inc. scores highest on Anchor (55) and lowest on Price (16). Its PosiPenta is 38.85 out of 100, weaker than most similar companies.
On the Penta Grid this week, IGC Pharma, Inc. is Grid #573 of 837 in the Healthcare sector in United States, and Grid #2,989 of 4,000 in United States.
Compared with similar companies in the Healthcare sector in United States.
The five pillars
Similar companies
| Company | PosiPenta | P | E | N | T | A |
|---|---|---|---|---|---|---|
| IGC Pharma, Inc. | 38.85 | 16 | 46 | 39 | 39 | 55 |
| PetMed Express, Inc. | 44.68 | 38 | 59 | 21 | 52 | 52 |
| MIRA Pharmaceuticals, Inc. | 40.02 | 20 | 55 | 27 | 51 | 46 |
| DocGo Inc. | 39.62 | 49 | 57 | 19 | 33 | 40 |
| Atossa Therapeutics, Inc. | 37.28 | 38 | 28 | 27 | 60 | 34 |
| ABVC BioPharma, Inc. | 38.47 | 25 | 40 | 31 | 39 | 57 |
Similar-sized companies in the same sector, this week. P Price · E Earnings · N Nitro · T Torque · A Anchor.
Details
PPrice
| P/E ratio | -3.51 |
| P/B ratio | 4.16 |
EEarnings
| Trailing EPS | ₹-6.63 |
| Forward EPS | ₹-7.58 |
NNitro
| Price | 23.30 |
| 52-week high | 42.62 |
| 52-week low | 22.73 |
| Fall from 52-week high | 45.3% |
TTorque
| Return on equity (ROE) | -83.34% |
| Debt-to-equity | 0.18 |
AAnchor
| Beta (price swings) | 0.48 |
| Market cap | ₹240 Cr |
| Insider holding | 13.17% |
| Dividend yield | 0.00% |
Figures as used for the week of 17 Oct 2026; today's figures on the company page may differ slightly.
Questions
What is IGC Pharma, Inc.'s PosiPenta score?
IGC Pharma, Inc.'s PosiPenta is 38.85 out of 100 for the week of 17 Oct 2026, based on 5 of 5 pillars.
Where does IGC Pharma, Inc. stand on the Penta Grid?
On the Penta Grid this week, IGC Pharma, Inc. is Grid #573 of 837 in the Healthcare sector in United States, and Grid #2,989 of 4,000 in United States.
Which PosiPenta pillar is strongest for IGC Pharma, Inc.?
Anchor (stability and dividends), with a score of 55 out of 100: around the middle of similar companies.
Which PosiPenta pillar is weakest for IGC Pharma, Inc.?
Price (valuation), with a score of 16 out of 100: much weaker than most similar companies.
PositoAI is for research and education only and is not investment advice.